Modification of ERα by UFM1 Increases Its Stability and Transactivity for Breast Cancer Development |
Yoo, Hee Min
(School of Biological Sciences, Seoul National University)
Park, Jong Ho (School of Biological Sciences, Seoul National University) Kim, Jae Yeon (School of Biological Sciences, Seoul National University) Chung, Chin Ha (School of Biological Sciences, Seoul National University) |
1 | Le Romancer, M., Poulard, C., Cohen, P., Sentis, S., Renoir, J., and Corbo, L. (2011). Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr. Rev. 32, 597-622. DOI |
2 | Lemaire, K., Moura, R.F., Granvik, M., Igoillo-Esteve, M., Hohmeier, H.E., Hendrickx, N., Newgard, C.B., Waelkens, E., Cnop, M., and Schuit, F. (2011). Ubiquitin fold modifier 1 (UFM1) and its target UFBP1 protect pancreatic beta cells from ER stress-induced apoptosis. PLoS One 6, e18517. DOI |
3 | Liu, J., Guan, D., Dong, M., Yang, J., Wei, H., Liang, Q., Song, J., Xu, L., Bai, J., Liu, C., et al. (2020). UFMylation maintains tumor suppressor p53 stability by antagonizing its ubiquitination. Nat. Cell Biol. 22, 1056-1063. DOI |
4 | Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995). The nuclear receptor superfamily: the second decade. Cell 83, 835-839. DOI |
5 | Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., and Gustafsson, J.A. (2001). Mechanisms of estrogen action. Physiol. Rev. 81, 1535-1565. DOI |
6 | Preisler-Mashek, M.T., Solodin, N., Stark, B.L., Tyriver, M.K., and Alarid, E.T. (2002). Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am. J. Physiol. Endocrinol. Metab. 282, E891-E898. DOI |
7 | Yoo, H.M., Kang, S.H., Kim, J.Y., Lee, J.E., Seong, M.W., Lee, S.W., Ka, S.H., Sou, Y., Komatsu, M., Tanaka, K., et al. (2014). Modification of ASC1 by UFM1 is crucial for ERα transactivation and breast cancer development. Mol. Cell 56, 261-274. DOI |
8 | Yoo, H.M., Park, J.H., Jeon, Y.J., and Chung, C.H. (2015). Ubiquitin-fold modifier 1 acts as a positive regulator of brest cancer. Front. Endocrinol. (Lausanne) 6, 36. DOI |
9 | Zhang, Y., Zhang, M., Wu, J., Lei, G., and Li, H. (2012). Transcriptional regulation of the Ufm1 conjugation system in response to disturbance of the endoplasmic reticulum homeostasis and inhibition of vesicle trafficking. PLoS One 7, e48587. DOI |
10 | Colin, E., Daniel, J., Ziegler, A., Wakim, J., Scrivo, A., Haak, T.B., Khiati, S., Denomme, A., Amati-Bonneau, P., Charif, M., et al. (2016). Biallelic variants in UBA5 reveal that disruption of the UFM1 cascade can result in early-onset encephalopathy. Am. J. Hum. Genet. 99, 695-703. DOI |
11 | Daniel, J. and Liebau, E. (2014). The ufm1 cascade. Cells 3, 627-638. DOI |
12 | Zhou, W. and Slingerland, J.M. (2014). Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat. Rev. Cancer 14, 26-38. DOI |
13 | Hamilton, E.M.C., Bertini, E., Kalaydjieva, L., Morar, B., Dojcakova, D., Liu, J., Vandeever, A., Curiel, J., Persoon, C.M., Diadato, D., et al. (2017). UFM1 founder mutation in the Roma population causes recessive variant of H-ABC. Neulorogy 89, 1821-1828. |
14 | Komatsu, M., Chiba, T., Tatsumi, K., Iemura, S., Tanida, I., Okazaki, N., Ueno, T., Kominami, E., Natsume, T., and Tanaka, K. (2004). A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 23, 1977-1986. DOI |
15 | Lin, J., Xie, X., Weng, X., Qiu, S., Yoon, C., Lian, N., Xie, J., Wang, J., Lu, J., Chen, Q., et al. (2019). UFM1 suppressed invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling. J. Exp. Clin. Cancer Res. 38, 410. DOI |
16 | Jozwik, K.M. and Carroll, J.S. (2012). Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12, 381-385. DOI |
17 | Eckert, R.L., Mullick, A., Rorke, E.A., and Katzenellenbogen, B.S. (1984). Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114, 629-637. DOI |
18 | Gannavaram, S., Connelly, P.S., Daniels, M.P., Duncan, R., Salotra, P., and Nakhasi, H.L. (2012). Deletion of mitochodrial associated ubiquitin fold modifier protein Ufm1 in Leishmania donovani results in loss of beta-oxidation of fatty acid and blocks cell division in the amastigote stage. Mol. Microbiol. 86, 187-198. DOI |
19 | Hu, Z., Wang, X., Li, D., Cao, L., Cui, H., and Xu, G. (2021). UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2. Oncogene 40, 647-662. DOI |
20 | Jensen, E. (2012). A conversation with Elwood Jensen. Interview by David D. Moore. Annu. Rev. Physiol. 74, 1-11. DOI |
21 | Kang, S.H., Kim, G.R., Seong, M., Baek, S.H., Seol, J.H., Bang, O.S., Ovaa, H., Tatsumi, K., Komatsu, M., Tanaka, K., et al. (2007). Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J. Biol. Chem. 282, 5256-5262. DOI |
22 | Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J.A. (1996). Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93, 5925-5930. DOI |
23 | Heride, C., Urbe, S., and Clague, M.J. (2014). Ubiquitin code assembly and disassembly. Curr. Biol. 24, R215-R220. |
24 | Qin, B., Yu, J., Nowsheen, S., Wang, M., Tu, X., Liu, T., Li, H., Wang, L., and Lou, Z. (2019). UFL1 promotes histone H4 ufmylation and ATM activation. Nat. Commun. 10, 1242. DOI |
25 | Reid, G., Hubner, M.R., Metivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J., and Gannon, F. (2003). Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11, 695-707. DOI |
26 | Song, A., Wang, Y., Jiang, F., Yan, E., Zhou, J., Ye, J., Zhang, H., Ding, X., Li, G., Wu, Y., et al. (2021). Ubiquitin D promotes progression of oral squamous cell carcinoma via NF-kappa B signaling. Mol. Cells 44, 468-480. DOI |
27 | Tatsumi, K., Yamamoto-Mukai, H., Shimizu, R., Waguri, S., Sou, Y.S., Sakamoto, A., Taya, C., Shitara, H., Hara, T., Chung, C.H., et al. (2011). The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. Nat. Commun. 2, 181. DOI |
28 | Wang, Z., Gong, Y., Peng, B., Shi, R., Fan, D., Zhao, H., Zhu, M., Zhang, H., Lou, Z., Zhou, J., et al. (2019). MRE11 ufmylation promotes ATP activation. Nucleic Acids Res. 47, 4124-4135. DOI |